1.
Yu L, Lutz MW, Wilson RS, et al. APOE ε4-TOMM40 ’523 haplotypes and the risk of Alzheimer’s disease in older Caucasian and African Americans. PLoS One. 2017;12(7):e0180356. doi:10.1371/journal.pone.0180356.
1.
Yang H-S, Yu L, White CC, et al. Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: a community-based cohort study. Lancet Neurol. 2018;17(9):773-781. doi:10.1016/S1474-4422(18)30251-5.
1.
Oveisgharan S, Buchman AS, Yu L, et al. ε2ε4 genotype, incident AD and MCI, cognitive decline, and AD pathology in older adults. Neurology. 2018;90(24):e2127-e2134. doi:10.1212/WNL.0000000000005677.
1.
Bennett DA, Yu L, Yang J, Srivastava GP, Aubin C, De Jager PL. Epigenomics of Alzheimer’s disease. Transl Res. 2015;165(1):200-20. doi:10.1016/j.trsl.2014.05.006.
1.
Jun G, Ibrahim-Verbaas CA, Vronskaya M, et al. A novel Alzheimer disease locus located near the gene encoding tau protein. Mol Psychiatry. 2016;21(1):108-17. doi:10.1038/mp.2015.23.
1.
Ramanan VK, Risacher SL, Nho K, et al. GWAS of longitudinal amyloid accumulation on 18F-florbetapir PET in Alzheimer’s disease implicates microglial activation gene IL1RAP. Brain. 2015;138(Pt 10):3076-88. doi:10.1093/brain/awv231.
1.
Yu L, Boyle PA, Nag S, et al. APOE and cerebral amyloid angiopathy in community-dwelling older persons. Neurobiol Aging. 2015;36(11):2946-53. doi:10.1016/j.neurobiolaging.2015.08.008.
1.
Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420-4. doi:10.1038/nature17946.